The Latest Breaking News from PFE

Pfizer (PFE) played a pivotal role in developing vaccines and pills that helped the world return to normal from the COVID-19 pandemic. The company reported record revenue and earnings in fiscal 2022. Given the company’s solid growth prospects, it could be wise to invest in the stock right now. Keep…

With Russia’s plans to cut crude oil production threatening to tip an interest-rate-paranoid market into a fresh bout of volatility and sell-off, shares of fundamentally strong and profitable businesses, such as Taiwan Semiconductor Manufacturing Company (TSM), Walmart (WMT), and Pfizer (PFE), seem to be good investments now. Continue reading….

Looming recession fears, the Federal Reserve’s persistent monetary tightening plans, and stubbornly high inflation continue to impact investor sentiment. Hence, it could be wise to add fundamentally sound stocks Pfizer (PFE), Rio Tinto (RIO), and Lockheed Martin (LMT) to beat the market fluctuations this year. Continue reading….

Pfizer (PFE) topped Wall Street’s EPS and revenue estimates in the third quarter. Moreover, the company updated its guidance for fiscal 2022. Analysts expect the stock to rise more than 16% in the near term. Therefore, it could be wise to buy the stock now. Keep reading….

Rising chronic diseases, an aging population, and surging healthcare spending should boost the pharmaceutical industry’s growth prospects. Moreover, the pharmaceutical industry usually holds up well during market downturns due to relatively inelastic demand for their products and services. Therefore, fundamentally sound pharma stocks Johnson & Johnson (JNJ), AbbVie (ABBV), and…

Places for Everyone - the conurbation’s controversial long-term strategy for jobs and homes - is currently undergoing a public examination as part of the process towards it being signed off by the government.

The Fed’s indication to keep raising interest rates through this year and looming recession fears will likely keep the stock market under pressure for the near term. Therefore, investors looking for stability amid an uncertain macroeconomic environment could consider buying fundamentally strong dividend-paying healthcare stocks Johnson & Johnson (JNJ), Pfizer…

Although inflation moderated for the sixth consecutive month in December, a recession is still likely as the Fed is expected to keep raising rates this year. Amid an uncertain economic backdrop, fundamentally strong and popular stocks on Wall Street, Microsoft (MSFT), Pfizer (PFE), and AT&T (T), could make ideal additions…

While inflation has been showing signs of cooling recently, it is still far beyond the Fed’s target rate. Consequently, the Fed is expected to keep raising the interest rates for some time, fueling the chances of a global recession. Therefore, it could be wise to invest in well-performing stocks Pfizer…